Catalog record · Risk Management
Stage as of source date not established · historical report, not live reconfirmation.
Novartis trial-operations risk and data-quality monitoring
Primary workflow source. A named organization's workflow supported by a reviewed primary source. Stage is reported separately; this label does not establish measured outcomes or independent validation.
Last researched Oct 26, 2026. Source access and reported stage are recorded below; deployment evidence does not establish ROI.
What the research supports
SENSE gives trial managers operational risk signals, missing/out-of-sequence activity checks and drill-down views.
- Reported stage
- Scaled
- Technology
- Machine Learning
- Business function
- Middle Office
- Impact (legacy label)
- Not labeled
- Catalog date · unconfirmed
- Not reported
- Imported
- Oct 29, 2026
- Last researched
- Oct 26, 2026
Measures & evidence
No quantified measure recorded. This is a gap in the evidence, not a finding of no value.
Documented vendor relationships
No vendor relationship has been linked to this specific workflow in the curated overlay. This does not mean it was built without vendors.
See the company’s documented relationshipsDeployment evidence & limits
Issuer describes launched operational data-quality features and more than 2,500 users; later issuer material confirms AI-enhanced trial-risk analytics. Status date not established.
Stage is as reported in the cited evidence. Current operating status has not been independently reconfirmed; the research date is an editorial review date.
Novartis explicitly describes extensive historical data curation and source-quality dependence; dashboard improvements alone are not evidence of AI causation. Historical 2,500-user scale is not claimed as a 2026 count; later article does not quantify current SENSE adoption. Data standardization is a major prerequisite; apparent discrepancy reductions may reflect cleanup effort, not model accuracy or prevented loss.
Potential FS application · inferred
Inferred: Monitor large regulatory-remediation programs: detect missing evidence, out-of-order milestones and forecast completion risks.
A common event/data model plus predictive alerts focuses manager attention on exceptions across many workstreams.
Original industry: Pharmaceuticals and biotechnology. Transfer limits: Data standardization is a major prerequisite; apparent discrepancy reductions may reflect cleanup effort, not model accuracy or prevented loss.
Recorded dependencies
- Traceable source data and approved document/control schemas
- Qualified human review and local testing of accuracy, omissions and full workflow effort
Source register
- The Power of Transparency | How Nerve Live Transforms Clinical Trialslive.novartis.com · opens in a new tab
Novartis · issuer · full-text · Publication date not recorded
- Smarter decisions at scale: How Novartis is using AI to advance R&Dnovartis.com · opens in a new tab
Novartis · issuer · full-text · Publication date not recorded
Research lanes: health_life_sciences · Batch global-discovery-2026-10-26. Coverage and remaining gaps